Home
Company
Our Vision
Our Leadership Team
Naronapride (ATI-7505)
About Naronapride (ATI-7505)
Mechanism of Action
Development Status
Chemistry and Manufacturing
Regulatory Developments
Knowledge Centre
Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
Gastroparesis
Chronic Idiopathic Constipation
Irritable Bowel Syndrome
PPI non-responsive GERD
Functional Dyspepsia
News
Press
>
Renexxion Ireland Announces Issuance of Two U.S. Patents Covering a Novel Crystal Isoform of Naronapride
Renexxion to Present at the Oppenheimer Healthcare Private Company Showcase
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
Contact
Contact
Renexxion Ireland Limited
Carlton House, 4th Floor
Henry Street
Limerick
V94 FD80
Ireland
+353 61 539121
Business Development enquiries
:
bd(at)rnexltd(dot)ie
Press and media enquiries
:
press(at)rnexltd(dot)ie
Please replace (at) and (dot) with their respective symbols (e.g. example@rnextltd.ie)
*
Indicates required field
Name
*
First
Last
Email
*
Comment
*
Submit
Home
Company
Our Vision
Our Leadership Team
Naronapride (ATI-7505)
About Naronapride (ATI-7505)
Mechanism of Action
Development Status
Chemistry and Manufacturing
Regulatory Developments
Knowledge Centre
Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
Gastroparesis
Chronic Idiopathic Constipation
Irritable Bowel Syndrome
PPI non-responsive GERD
Functional Dyspepsia
News
Press
>
Renexxion Ireland Announces Issuance of Two U.S. Patents Covering a Novel Crystal Isoform of Naronapride
Renexxion to Present at the Oppenheimer Healthcare Private Company Showcase
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
Contact